- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01098643
Satisfaction With Placement of Implantable Venous Access Devices in Patients With Solid Tumors
Patient Satisfaction With Placement of Implantable Venous Access Devices
RATIONALE: Gathering information about patients with solid tumors who have implantable venous access devices may help doctors learn more about patient satisfaction.
PURPOSE: This phase I trial is studying satisfaction with placement of implantable venous access devices in patients with solid tumors.
Study Overview
Status
Detailed Description
OBJECTIVES:
- To determine patient satisfaction with subcutaneous venous-access device placement in oncology patients.
OUTLINE: Patients complete a computer-based survey while in the treatment area of the Vanderbilt Oncology Clinic. Basic demographic information and basic information regarding the placement of the device and complications are collected from the patient's medical record.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-6838
- Vanderbilt-Ingram Cancer Center
-
Nashville, Tennessee, United States, 37064
- Vanderbilt-Ingram Cancer Center - Cool Springs
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis of a solid tumor malignancy
- No hematological malignancy
- Patient at the Vanderbilt Oncology Clinic
Has undergone placement of a subcutaneous, single-lumen venous-access device within the past 6 months
- No patients who have had ≥ 2 venous-access devices placed by ≥ 1 department
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Not currently undergoing preparation for or process of stem cell transplantation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall satisfaction with port placement
Time Frame: n/a - study closed
|
n/a - study closed
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Frequency of complications
|
|
Frequency of port failure
|
|
Need for removal of device
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kristin Ancell, MD, Vanderbilt-Ingram Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CDR0000669012
- P30CA068485 (U.S. NIH Grant/Contract)
- VU-VICC-SUPP-0982
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Adult Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingUnspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on medical chart review
-
M.D. Anderson Cancer CenterTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Central Nervous System Neoplasm | Malignant Skull Base NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLCCompletedIncidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin AmericaHIV Infection | Malignant Neoplasm | Recurrent Malignant Neoplasm | Human Immunodeficiency Virus 1 PositiveMexico, Argentina, Brazil
-
M.D. Anderson Cancer CenterRecruitingCutaneous MelanomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Sarcoma | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Recurrent Cervical Carcinoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Stage I Uterine... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingEvaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans SyndromeBronchiolitis ObliteransUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm | Malignant Respiratory Tract Neoplasm | Malignant Thoracic NeoplasmUnited States, Cyprus